|
 |
European Pharmaceutical Contractor
|
The international pharmaceutical industry is one of the most highly R&D-intensive, more so than the electronics, communications and aerospace industries. The pharma industry faces a continuing challenge to employ the right kind of people, as market leadership depends not only on highly specialised skills, but also on experience.
US Dominance
US pharmaceutical companies are the leaders in the global pharmaceutical industry and this is expected to continue in the future (1). The ability to invest substantially in R&D is critical to a company's future growth potential. With the advantage of having the lion's share of the bestselling products, US companies have been in a stronger position to spend more on R&D than their European and Japanese rivals.
In 2001, the US pharmaceutical industry invested more than US$30 billion in discovering and developing new medicines (2). This high level of R&D investment resulted in increased productivity, hence the US pharmaceutical industry has generated more novel drug substances than its European and Japanese counterparts in each five year period since 1965 (1, 3).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Faiz Kermani, Budgets Proposals and Marketing Executive, Linda White, Head of Contract Personnel, and Pietro Bonacossa, Marketing Executive, at Chiltern International
Dr Faiz Kermani currently works in Business Development at Chiltern International where his role covers bids, proposals and marketing. He previously worked in Business Development at CMR International, examining R&D productivity issues for pharmaceutical industry clients.
Faiz has also worked as a Research Analyst for a Danish health care consultancy, Informedica A/S, focusing on global pharmaceutical pricing and parallel importation.
He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.
Linda White is Head of the Contract Personnel Department at Chiltern International. Following on from a degree in Psychology, she spent several years looking at psychometric testing in clinical trials. Linda joined Chiltern in 1997, initially in Quality Assurance, before being given the opportunity to develop the Contract Personnel Department a year later.
Pietro Bonacossa is a Marketing Executive at Chiltern International in Atlanta, USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, Pietro spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
